‌

US Patent 11673894 Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

Patent 11673894 was granted and assigned to Incyte on June, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Date of Patent

June 13, 2023

0

Patent Application Number

170777130

Date Filed

October 22, 2020

0

Patent Citations

US Patent 7635757 B7-4 Antibodies and uses therefor

0

US Patent 7674791 Triazolopyrazines and methods of making and using the same

0

US Patent 7700594 Fused bicyclic mTOR inhibitors

0

US Patent 7709468 Imidazo based heterocycles

0

US Patent 7722868 Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereof

0

US Patent 7834014 A

0

US Patent 7943743 Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

0

US Patent 8008449 Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics

0

...

Patent Citations Received

US Patent 11884665 Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors

0

US Patent 11999740 Fused pyrazine derivatives as A2A / A2B inhibitors

0

US Patent 11873304 Fused pyrimidine derivatives as A2A/A2B inhibitors

0

Patent Primary Examiner

Clinton A Brooks

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11673894 Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool